FDA naming proposal would decrease competition, FTC says
The staffs of three Federal Trade Commission offices argue that a Food and Drug Administration proposal on naming certain biological products could cause decreased price competition....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch